Orantinib (TSU-68)

DRUG2 trials

Sponsors

Taiho Pharmaceutical Co., Ltd.

Conditions

Hepatocellular Carcinoma

Phase 1

Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma

CompletedNCT00784290

Taiho Pharmaceutical Co., Ltd.Hepatocellular Carcinoma

Start: 2003-09-30End: 2012-03-31Updated: 2012-03-26

Phase 3

Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

TerminatedNCT01465464

Taiho Pharmaceutical Co., Ltd.Hepatocellular Carcinoma

Start: 2010-12-31End: 2014-11-30Updated: 2019-08-07

Related Papers

Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

2017-10-04146 citations

Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.

2011-09-214 citations